308 related articles for article (PubMed ID: 27267714)
21. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
Pinkerton JV; Komm BS; Mirkin S
Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
[TBL] [Abstract][Full Text] [Related]
22. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
Pickar JH; Lavenberg J; Pan K; Komm BS
Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
[TBL] [Abstract][Full Text] [Related]
23. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
Umland EM; Karel L; Santoro N
Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
[TBL] [Abstract][Full Text] [Related]
24. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
Archer DF; Lewis V; Carr BR; Olivier S; Pickar JH
Fertil Steril; 2009 Sep; 92(3):1039-1044. PubMed ID: 19635614
[TBL] [Abstract][Full Text] [Related]
25. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
Kagan R
J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
[TBL] [Abstract][Full Text] [Related]
26. Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract.
Barrera J; Chambliss KL; Ahmed M; Tanigaki K; Thompson B; McDonald JG; Mineo C; Shaul PW
Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E345-54. PubMed ID: 24939737
[TBL] [Abstract][Full Text] [Related]
27. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
28. Differential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma.
Flannery CA; Saleh FL; Choe GH; Selen DJ; Kodaman PH; Kliman HJ; Wood TL; Taylor HS
J Clin Endocrinol Metab; 2016 Jul; 101(7):2883-91. PubMed ID: 27088794
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Chang KC; Wang Y; Bodine PV; Nagpal S; Komm BS
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):117-24. PubMed ID: 19914376
[TBL] [Abstract][Full Text] [Related]
30. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
Stovall DW
Curr Opin Investig Drugs; 2010 Apr; 11(4):464-71. PubMed ID: 20336595
[TBL] [Abstract][Full Text] [Related]
31. Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Zhang SQ; Cai B; Liu L; He YY; Yang YX; Wan XP
Int J Gynecol Cancer; 2009 Nov; 19(8):1377-83. PubMed ID: 20009893
[TBL] [Abstract][Full Text] [Related]
32. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.
Komm BS; Mirkin S
Int J Womens Health; 2012; 4():129-40. PubMed ID: 22505832
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of menopausal therapies on the endometrium.
Mirkin S; Archer DF; Taylor HS; Pickar JH; Komm BS
Menopause; 2014 Aug; 21(8):899-908. PubMed ID: 24518153
[TBL] [Abstract][Full Text] [Related]
34. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
35. Advances in menopausal therapy: the tissue-selective estrogen complex.
Moore A
J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone.
Kannan A; Bhurke A; Sitruk-Ware R; Lalitkumar PG; Gemzell-Danielsson K; Williams ARW; Taylor RN; Bagchi MK; Bagchi IC
Reprod Sci; 2018 Mar; 25(3):320-328. PubMed ID: 29241443
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro.
Song Y; Santen RJ; Wang JP; Yue W
Endocrinology; 2013 Feb; 154(2):656-65. PubMed ID: 23254198
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis.
Kato N; Iwase A; Ishida C; Nagai T; Mori M; Bayasula ; Nakamura T; Osuka S; Ganiyeva U; Qin Y; Miki R; Kikkawa F
Reprod Sci; 2019 Jul; 26(7):979-987. PubMed ID: 30270745
[TBL] [Abstract][Full Text] [Related]
39. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.
Sakr S; Naqvi H; Komm B; Taylor HS
Endocrinology; 2014 Apr; 155(4):1489-97. PubMed ID: 24484171
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
